Rosalind Advisors, Inc. — 13F Holdings & Portfolio

CIK 1622627 · latest 13F-HR filed 2026-08-14

Rosalind Advisors, Inc. manages $269.2M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DCTH (15.44%), FENC (12.73%), XERS (8.56%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 6; 15 existing positions rose in reported value and 8 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$269.2M

Long-equity book

Holdings
35

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+3 / −6 / ↑15 / ↓8

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 74.9%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Rosalind Advisors, Inc. Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 DELCATH SYSTEMS, INC. DCTH 24661P807 $41.6M 15.44% 3,300,389 SH
2 FENNEC PHARMACEUTICALS INC FENC 31447P100 $34.3M 12.73% 3,188,001 SH
3 XERIS BIOPHARMA HOLDINGS INC XERS 98422E103 $23.0M 8.56% 2,908,981 SH
4 SAVARA INC SVRA 805111101 $19.6M 7.27% 3,178,121 SH
5 VERASTEM INC VSTM 92337C203 $15.2M 5.66% 3,986,509 SH
6 X4 PHARMACEUTICALS INC XFOR 98420X202 $15.0M 5.58% 3,214,766 SH
7 EYEPOINT PHARMACEUTICALS INC EYPT 30233G209 $14.1M 5.25% 988,230 SH
8 CYBIN INC HELP 23256X407 $12.9M 4.80% 1,956,814 SH
9 VOR BIOPHARMA INC VOR 929033207 $11.9M 4.44% 648,600 SH
10 VAXCYTE INC PCVX 92243G108 $11.6M 4.32% 200,000 SH
11 MEDIWOUND LTD MDWD M68830112 $11.0M 4.09% 749,054 SH
12 CELLDEX THERAPEUTICS INC CLDX 15117B202 $7.4M 2.76% 200,000 SH
13 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $7.2M 2.68% 721,504 SH
14 PROFOUND MEDICAL CORP PROF 74319B502 $5.5M 2.05% 828,118 SH
15 TALPHERA INC TLPH 00444T209 $5.3M 1.98% 5,169,501 SH
16 ATEA PHARMACEUTICALS INC AVIR 04683R106 $5.0M 1.85% 1,070,550 SH
17 MYOMO INC MYO 62857J201 $3.8M 1.41% 3,637,886 SH
18 OVID THERAPEUTICS INC OVID 690469101 $3.0M 1.11% 1,107,994 SH
19 NEURAXIS INC NRXS 64134X201 $3.0M 1.10% 508,055 SH
20 ABIVAX SA ABVX 00370M103 $2.8M 1.03% 20,869 SH
21 INSPIREMD INC NSPR 45779A846 $2.7M 1.02% 3,905,743 SH
22 REGENTIS BIOMATERIALS LTD RGNT M8211G108 $2.5M 0.92% 701,685 SH
23 SELLAS LIFE SCIENCES GROUP INC Put SLS 81642T959 $2.3M 0.86% 568,700 SH
24 POLYPID LTD PYPD M8001Q126 $2.0M 0.73% 389,455 SH
25 BIOFRONTERA INC BFRI 09077D209 $1.2M 0.45% 1,275,609 SH
26 KURA ONCOLOGY INC KURA 50127T109 $1.1M 0.41% 100,000 SH
27 SPRUCE BIOSCIENCES INC SPRB 85209E208 $1.1M 0.40% 20,000 SH
28 AQUESTIVE THERAPEUTICS INC AQST 03843E104 $1.0M 0.39% 250,000 SH
29 ONKURE THERAPEUTICS INC OKUR 68277Q105 $684.0K 0.25% 150,000 SH
30 PEPGEN INC PEPG 713317105 $630.0K 0.23% 350,000 SH
31 CG ONCOLOGY INC Call CGON 156944900 $375.1K 0.14% 31,000 SH
32 EYEPOINT PHARMACEUTICALS INC Call EYPT 30233G909 $130.8K 0.05% 50,300 SH
33 ISHARES TR Put IFXAF 464287955 $110.0K 0.04% 500,000 SH
34 SPDR SERIES TRUST Put GLD 78464A950 $35.1K 0.01% 140,600 SH
35 TENAX THERAPEUTICS INC Put TENX 88032L955 $13.9K 0.01% 6,200 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $269.2M 35 0001622627-26-000022
2026-03-31 2026-05-14 $248.9M 38 0001622627-26-000015
2025-12-31 2026-02-12 $284.5M 42 0001622627-26-000011
2025-09-30 2025-11-13 $292.6M 39 0001622627-25-000038
Filer Information
Address
15 WELLESLEY STREET WEST
SUITE 326
TORONTO M4Y 0G7
Phone
(416) 791-0300
Filing Manager
Rosalind Advisors, Inc.
TORONTO, A6
Signatory
Steven Salamon
President, Rosalind Advisors, Inc.